Category Archives: Transhuman News

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced an interview with President and CEO Dr. James A. Hayward conducted by the BBCs Business Daily as part of an episode titled Tracing cottons DNA. The episode is available at https://www.bbc.co.uk/sounds/play/w3ct1jn9.

CertainT for Cotton Traceability

CertainT, Applied DNAs traceability platform, provides an approach to authenticate goods within large and complex supply chains for materials such as cotton, and leather, home textiles and apparel, pharmaceuticals and nutraceuticals, personal care, cannabis, and other products. To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.

CertainT begins by authenticating the fiber content in cotton to confirm its origin. The platform then employs a unique molecular identifier produced by the Companys LinearDNA platform to mark cotton fibers in bulk. The cotton fiber is then tested for the presence of the identifier via the Companys proprietary, portable readers as the cotton fiber travels throughout a global supply chain and is converted into yarn, fabric, and finished goods. The detection of the identifier confirms origin and authenticity; its absence can signal for blending with illicit cotton, including cotton potentially produced by means of forced labor. The CertainT logo signifies to consumers of cotton products that they can trust the products they are buying with said trust grounded in forensic, science-based authentication. Consumers can therefore be confident in the knowledge that Brands and their supply chains have taken the necessary steps to assure that the cotton product itself is authentic and sustainably and responsibly sourced from a known origin.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Companys deep expertise in DNA.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Companys common stock is listed on NASDAQ under ticker symbol APDN, and its publicly traded warrants are listed on OTC under ticker symbol APPDW.

Applied DNA is a member of the Russell Microcap Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNAs future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, our ability to successfully enter into commercial contracts for the implementation of our CertainT platform, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNAs SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020 and our subsequent quarterly reports on Form 10-Q filed on February 11, 2021, and other reports we file with the SEC, which are available at http://www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Continue reading here:
Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily...

Enlarge / X-ray image of the mysterious fetus found in the coffin of the 17th-century Swedish Bishop Peder Winstrup.

Gunnar Menander

When Swedish archaeologists in 2015 X-rayed the remains of a 17th-century bishop, they were shocked when the images revealed that the bishop shared his coffin with the remains of a stillborn premature baby.Now, ancient DNA analysis has revealed that the fetus was likely the bishop's grandson, according toa new paper published in the Journal of Archaeological Science: Reports.

Born in Copenhagen in 1605, Bishop Peder Winstrupwas a prominent church figure in Denmark and Sweden during his lifetime, who helped found Lund University in 1666 while deftly navigating the constantly shifting political environment. (He was ennobled by the Swedish king, Charles X Gustav, when his diocese passed from Danish hands in 1658.) Winstrup died in late December 1679 and was buried in Lund Cathedral in January 1680. When his coffin was opened in the early 19th and 20th centuries, the body was remarkably well-preserved.

So when the curators of the Lund University Historical Museum heard, in 2012, that the bishop's coffin would be moved to a new burial site outside the cathedral, they joined with scientists in a multidisciplinary collaboration to study the bishop's remains before they were reinterred. The body was X-rayed and CT-scanned, along with the bishop's clothing, various artifacts, and plant and insect remains.

The scientists found that the bishop's body had not been embalmed. Rather, the body was placed on a mattress stuffed with herbs (like juniper and wormwood), with the head resting on a pillow of hops, which helped preserve itincluding the bishop's clothing, although the colors had faded. Theyalso found that Winstrup likely died of pneumonia and that he suffered from gout, arthritis, arterial plaque, and gallstones (a sign of a diet high in fatty foods), among other illnesses. He had also lost many teeth, and those that remained showed signs of decay, indicating the bishop was fond of sweets. (The coffin contained a small pouch holding several teeth.)

The bishop's lungs also proved to be remarkably well-preserved, and anthropologists found small calcifications in those lungsevidence of a prior infection, most likely tuberculosis. The anthropologists surmised that Winthrop likely contracted the disease during the so-called "White Plague" epidemic that swept through Europe in the 17th century. In fact, last year, researchers at Lund University, the Max Planck Institute for the Science of Human History, and the Swedish Natural Historical Museum were able to reconstruct the genome for a TB sample (Mycobacterium tuberculosis) taken from one of those calcified nodules. Because the bishop's precise date of death is known, the team was able to determine that the TB pathogen is much younger than scientists previously believed.

But by far the most significant discovery was that the bishop was not alone in his coffin. The CT scans showed a linen-wrapped bundle containing the remains of a stillborn fetus (roughly five to six months along, in terms of development), nestled within the layers of herbs just under the bishop's right tibia. It was initially assumed that someone (unrelated to the bishop) had taken advantage of the bishop's burial to ensure their illegitimate offspring was buried on sanctified ground.

Bishop Peder Winstrup on a contemporary engraving printed in one of his own theological works in 1666.

Peder Winstrup in the coffin, where researchers also discovered a fetus wrapped in a bundle between his calves.

Gunnar Menander

The bundle found at the feet of the remains of Bishop Peder Winstrup.

Gunnar Menander

In fact, "It was not uncommon for small children to be placed in coffins with adults," said Torbjrn Ahlstrm, a professor of historical osteology at Lund University who co-authored the new study. "The fetus may have been placed in the coffin after the funeral, when it was in a vaulted tomb in Lund Cathedral and therefore accessible." That jibes with evidence that the wrapped fetus had been hastily placed in the coffin. And other coffins in the same vault also held remains of several children. But it would take ancient DNA analysis to definitively rule out the possibility that the fetus was related to Winstrupso that's whatAhlstrm and his colleagues set out to do.

The Lund researchers took DNA samples from Winstrup's right femur and the left femur of the fetus. They determined that the stillborn fetus was male and that there was a second-degree kinship with Winstrup, meaning that they shared about 25 percent of the same genes. There was a Y-chromosome match but the mitochondrial DNA was different, indicating the connection was on the paternal side of the family tree. The second-degree relationship could have been grandparent-grandchild, uncle-nephew, or even half siblings or double cousins.

To narrow the possibilities, Ahlstrm et al. turned to a close examination of the Winstrup family's genealogy. According to the genealogical records maintained at the House of Nobility in Stockholm, Sweden, the bishop was one of six children (four daughters and two sons). Since the Lund researchers were only concerned with paternal lineage, they could ignore the four sisters in their analysis. Winstrup's brother, Elias, died in 1633 at the age of 27, unmarried and childless. This enabled the Lund team to rule out certain possibilities: uncle/nephew, half siblings, and double cousins, specifically.

Bishop Peder Winstrup in turn fathered five children with his first wife, Anne Marie Ernstatter Baden, three of whom (two daughters and a son) survived to adulthood. He had no children with his second wife, Dorothea von Andersen.

So the most likely possible relationship, the authors concluded, was that Winstrup was the stillborn child's grandfatheri.e., the issue of his son, Peder Pedersen Winstrup, who bucked the family theological tradition to focus on military matters (particularly fortification), lost the family estate in the Great Reduction, and died destitute. However, there is a small likelihood that the fetus may have been that of the bishop's sister Anna Maria (who may have died in childbirth) and her husband Casper vonBhnen, assuming Casper belonged to a similar Y haplogroup.

As for how the fetus came to rest with the bishop, "It seems probable that the relatives would have had access to the crypt where the coffins of the Winstrups were stored, and, thus, a possibility to deposit the fetus in one of the coffins, in this case that of Peter Winstrup," the authors concluded.

DOI: Journal of Archaeological Science: Reports, 2021. 10.1016/j.jasrep.2021.102939 (About DOIs).

More:
DNA analysis solves curious case of the stillborn fetus in the bishops coffin - Ars Technica

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today will present data at the 2021 American Association for Cancer Research (AACR) Annual Meeting. The poster, Extrachromosomal DNA (ecDNA)-driven switching of oncogene dependency facilitates resistance to targeted therapy, is available to registered attendees today, from 8:30 a.m. 11:59 p.m. ET. AACR is being held virtually this year due to COVID-19.

The oncology field has long known that tumors with oncogene amplification are aggressive, lead to a poor prognosis, and are very difficult to treat, said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. This study provides rationale for why patients with oncogene amplified tumors have not benefited from targeted therapies. We have demonstrated that ecDNA facilitate a powerful evasive mechanism of switching driver oncogenes when under targeted therapeutic pressure, thereby rendering targeted therapies futile against ecDNA-enabled, gene amplified cancers. Our findings underscore an urgent need and Boundless Bios focus in developing precision medicines targeting the underlying vulnerabilities of ecDNA.

Study Summary

Oncogenes are frequently amplified on ecDNA, circular units of DNA that are separate from chromosomes and that are highly transcribed. Because ecDNA lack centromeres, during mitosis they are passed to daughter cells asymmetrically and can thereby lead to exponential increase in copy number of genes encoded on ecDNA, which in turn facilitates tremendous genomic heterogeneity in tumor cells. The tumor heterogeneity and plasticity enabled by ecDNA can provide a mechanism of resistance for cancer cells against cancer treatment. The study set out to understand the role of ecDNA in facilitating poor responses to targeted therapies in gene amplified cancer.

The study employed the SNU16 gastric cancer model, which contains MYC and FGFR2 amplification at baseline, to characterize ecDNA content, genomic heterogeneity, and ecDNA kinetics in forming resistance to targeted therapy. Boundless Bio scientists performed a longitudinal assessment of cellular resistance and ecDNA dynamics, initially in response to the FGFR2 inhibitor, infigratinib. Upon identifying EGFR amplification on ecDNA as the dominant mechanism of resistance to infigratinib, the study subsequently also evaluated response and resistance to the EGFR inhibitor, erlotinib, delivered either sequentially or in parallel with infigratinib.

The results from the study show differential and dose-dependent resistance of SNU16 cells to infigratinib driven by the heterogeneity of oncogenes residing on ecDNA. First, low doses of infigratinib led to additional amplification of FGFR2 on ecDNA that resulted in levels of FGFR2 that were able to outcompete the drug exposure. High doses of infigratinib resulted in amplification of a new oncogene, EGFR, on ecDNA, representing an ecDNA-mediated switching of oncogene dependency from FGFR2 to EGFR. Next, upon exposing the infigratinib resistant cells (now with EGFR amplification on ecDNA) to single agent EGFR inhibitor, erlotinib, the cells again became resistant, as the emergent ecDNA-enabled EGFR dependency switched back to the original FGFR2 dependency, again via amplification on ecDNA. Lastly, the study tested dual upfront inhibition of both FGFR2 and EGFR with infigratinib and erlotinib, respectively, in previously untreated SNU16 cells. Although initial cytotoxicity was more robust than with either agent alone, the cell population inevitably became resistant. Remarkably, resistance to the up-front dual blockade was also driven by ecDNA, with amplification of various oncogenes, including MET and KRAS, on ecDNA.

This study and its results build upon and confirm previous studies that observe similar dynamics of ecDNA-driven amplification under therapeutic pressure. Such findings help explain the lack of responses and short durations associated with treatment of gene amplified cancers with targeted therapies in the clinic. The inability to a priori predict which new oncogenes would amplify on ecDNA as a mechanism of resistance to single-agent or multi-target inhibition suggest that both sequential and combination approaches of oncogene targeted therapies are suboptimal, if not largely ineffective clinical strategies for patients with ecDNA-driven cancers. These findings highlight the urgent need to take a new therapeutic approach, one that disables the underlying ecDNA machinery used by the tumor cell to drive tumor growth and resistance.

About ecDNA

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA lacking centromeres but containing functional genes, including oncogenes, that are separated from tumor cell chromosomes. ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer. By leveraging the plasticity afforded by ecDNA, cancer has the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including chemotherapy, targeted therapy, immunotherapy, or radiation, making ecDNA one of cancer cells primary mechanisms of recurrence and treatment resistance. ecDNA are not found in healthy cells but are present in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit http://www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Follow this link:
Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for...

A woman who traveled with Kylr Yust on the day after Jessica Runions went missing in September of 2016 said she was scared for her life as Yust was behaving nervously and erratically.Crystal Taylor, Jessep Carters ex-wife, said they traveled to Kansas City so she and Carter could meet up with Yust at his grandfathers house on September 9, 2016. It was after one day after Runions went missing from a party in Kansas City, after leaving with Yust.Carter was Kylr Yusts half-brother. He died by suicide in the Jackson County jail in 2018.Yust is accused of killing Kara Kopetsky in 2007. She was last seen leaving Belton High School in May of that year. He's also accused of killing Runions. They were last seen leaving a party together in 2016. A mushroom hunter found their remains in a Cass County farm field in 2017.After leaving Yusts grandfathers house on Sept. 9, 2016, Carter, Taylor and Yust went to visit Jesseps uncles house, Taylor testified. At the house, Taylor said Yust told her he had broken up with Runions the week before.But, Taylor testified minutes later that Yust received a phone call at the house and overheard him say he had seen Runions that day.As they left Carters uncles house, she saw Yust hide something in the bushes.They returned to Yusts grandfathers house where Yust showed her downstairs to watch TV. Thats when Carter and Yust left for a time, then returned. Carter looked shocked and scared when he returned, Taylor said.Kind of like mind blown, Taylor said.Cass County prosecutor Ben Butler asked Taylor if Carters behavior stood out to her.Yeah, it did. For him to be scared was not like him, she said.[ OPENING STATEMENT UPDATES ] [ SECOND DAY UPDATES ] [ THIRD DAY UPDATES ] [ FOURTH DAY UPDATES ] [ FIRST WEEK RECAP ] [ SIXTH DAY RECAP ] Taylor testified the three traveled around Raytown, Kansas City, Lone Jack, then eventually back to Edwards, Missouri.Along the way, she said Yust asked Carter and Taylor to take the batteries out of their cell phones. She testified they stopped off at a cousins house in Lone Jack where Carter went in to get a gun and give it to her. Police pulled them over around 3:25 a.m., on Sept. 10, where police confiscated the gun on Taylor, and gave Carter a ticket for driving on a suspended license.They returned to Edwards, Missouri, dropped Yust off at a trailer, and gave him some food. Police caflled later that evening, to get statements from Carter and Taylor.Taylor testified in the year after September of 2016, Carters behavior became abusive. She eventually left him to go to a shelter.She later learned Carter was arrested for setting his uncle Pauls house on fire.Carter died by suicide in the Jackson County jail in 2018.The prosecution also called Jarrah Kennedy from the Kansas City Police Department Crime Lab to discuss DNA collected from a red and gray hoodie recovered found near Yust's grandfather's house.Kennedy said there was brownish and blackish staining with four areas of interest on the shirt. She testified genetic information from Yust and Runions was collected from several areas of the shirt.There was also a potential third profile in the genetic mix on the shirt, Kennedy said, but she said she cannot provide an assumption of who it is due to the minimal nature of DNA.Cass County prosecutor Julie Tolle also questioned Matthew Forrest, a former KCPD crime scene technician. In pictures taken by Forrest that were obtained through a search warrant on Sept. 11, 2016, a blister on inside of finger, scratch on side of face and redness on hand could be observed. The pictures were taken days after Runions went missing, and her SUV was found burned. Melanie Fields, KCPD Crime Scene Unit Supervisor, also testified on Sept. 13, 2016 a second search warrant was executed on Yust and more pictures were taken. In the pictures, Fields noticed burnt facial hair, singed hair and injuries to his hand.

A woman who traveled with Kylr Yust on the day after Jessica Runions went missing in September of 2016 said she was scared for her life as Yust was behaving nervously and erratically.

Crystal Taylor, Jessep Carters ex-wife, said they traveled to Kansas City so she and Carter could meet up with Yust at his grandfathers house on September 9, 2016. It was after one day after Runions went missing from a party in Kansas City, after leaving with Yust.

Carter was Kylr Yusts half-brother. He died by suicide in the Jackson County jail in 2018.

Yust is accused of killing Kara Kopetsky in 2007. She was last seen leaving Belton High School in May of that year. He's also accused of killing Runions. They were last seen leaving a party together in 2016. A mushroom hunter found their remains in a Cass County farm field in 2017.

After leaving Yusts grandfathers house on Sept. 9, 2016, Carter, Taylor and Yust went to visit Jesseps uncles house, Taylor testified. At the house, Taylor said Yust told her he had broken up with Runions the week before.

This content is imported from Twitter.You may be able to find the same content in another format, or you may be able to find more information, at their web site.

But, Taylor testified minutes later that Yust received a phone call at the house and overheard him say he had seen Runions that day.

This content is imported from Twitter.You may be able to find the same content in another format, or you may be able to find more information, at their web site.

As they left Carters uncles house, she saw Yust hide something in the bushes.

They returned to Yusts grandfathers house where Yust showed her downstairs to watch TV. Thats when Carter and Yust left for a time, then returned.

Carter looked shocked and scared when he returned, Taylor said.

Kind of like mind blown, Taylor said.

Cass County prosecutor Ben Butler asked Taylor if Carters behavior stood out to her.

Yeah, it did. For him to be scared was not like him, she said.

[ OPENING STATEMENT UPDATES ] [ SECOND DAY UPDATES ] [ THIRD DAY UPDATES ] [ FOURTH DAY UPDATES ] [FIFTH DAY UPDATES ] [ FIRST WEEK RECAP ] [ SIXTH DAY RECAP ]

Taylor testified the three traveled around Raytown, Kansas City, Lone Jack, then eventually back to Edwards, Missouri.

Along the way, she said Yust asked Carter and Taylor to take the batteries out of their cell phones. She testified they stopped off at a cousins house in Lone Jack where Carter went in to get a gun and give it to her. Police pulled them over around 3:25 a.m., on Sept. 10, where police confiscated the gun on Taylor, and gave Carter a ticket for driving on a suspended license.

They returned to Edwards, Missouri, dropped Yust off at a trailer, and gave him some food. Police caflled later that evening, to get statements from Carter and Taylor.

Taylor testified in the year after September of 2016, Carters behavior became abusive. She eventually left him to go to a shelter.

She later learned Carter was arrested for setting his uncle Pauls house on fire.

Carter died by suicide in the Jackson County jail in 2018.

The prosecution also called Jarrah Kennedy from the Kansas City Police Department Crime Lab to discuss DNA collected from a red and gray hoodie recovered found near Yust's grandfather's house.

Kennedy said there was brownish and blackish staining with four areas of interest on the shirt. She testified genetic information from Yust and Runions was collected from several areas of the shirt.

There was also a potential third profile in the genetic mix on the shirt, Kennedy said, but she said she cannot provide an assumption of who it is due to the minimal nature of DNA.

This content is imported from Twitter.You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Cass County prosecutor Julie Tolle also questioned Matthew Forrest, a former KCPD crime scene technician.

In pictures taken by Forrest that were obtained through a search warrant on Sept. 11, 2016, a blister on inside of finger, scratch on side of face and redness on hand could be observed. The pictures were taken days after Runions went missing, and her SUV was found burned.

This content is imported from Twitter.You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Melanie Fields, KCPD Crime Scene Unit Supervisor, also testified on Sept. 13, 2016 a second search warrant was executed on Yust and more pictures were taken. In the pictures, Fields noticed burnt facial hair, singed hair and injuries to his hand.

This content is imported from Twitter.You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Read the rest here:
THE TRIAL OF KYLR YUST: DNA experts testify on evidence linking Yust to Runions death - KMBC Kansas City

Theres a new crime-fighting tool being used by the Santa Barbara County Sheriffs Office and for the first time, its being used in a cold case.

The ANDE rapid DNA instrument is being used in the cold case homicide of Paul Ornelas.

The 16-year-old Goleta resident was found dead more than four decades ago and his killer was never found. Ornelas's body was discovered near the train tracks below the Turnpike Road overpass on June 21, 1975.

Detective Matt Maxwell, assigned to the Major Crimes Bureau, is working on the reopened case.

Santa Barbara County Sheriff's Office

Ive been in contact with his family and the thing that they've expressed to me, more than anything, is just that the grieving process has never ended for them. They never got the closure, Detective Maxwell said.

The rapid DNA instrument, created by a Colorado-based company, is designed to identify decedents and solve crimes.

If you touch a handgun or a steering wheel of a car, we can collect DNA from that, said Sgt. Jarrett Morris of the Santa Barbara County Sheriffs Office Coroners Bureau.

Tissue samples, blood samples, or touch samples along with buccal swabs will work.

If we have a sample from like a suspect, we obtain a cheek swab from them and that generates a profile and I can compare it with any profiles we generated from any evidence that was collected, said Detective Brice Bruening of the Coroners Bureau.

ANDE

The Santa Barbara County Sheriffs Office was first introduced to the rapid technology back in 2019 following the deadly Conception boat fire.

That helped us identify all 34 decedents of that boat fire within a matter of days, Sgt. Morris said.

In January of 2020, they drove it down to Calabasas to help identify those killed in the Kobe Bryant helicopter crash.

Its since been used in a variety of local homicide cases, felony cases, some misdemeanor cases, and several decedent ID cases.

They even helped the San Luis Obispo County Sheriffs Office identify a human foot found in Templeton that was linked to a car crash last summer.

We can run five different cases through this instrument, Sgt. Morris said.

The biggest benefit is that it cuts down on time, bringing detectives the name of the suspect, for example, much quicker.

We get results in a matter of hours so at the most, two hours, Sgt. Morris said.

Normally, they would have to send the samples to labs, taking weeks or months to get the results back.

We're able to get these answers and able to move forward whether it's a criminal investigation or again, just bringing closure to a family, Sgt. Morris added.

As for the Ornelas case, the goal is to do just that - get the case solved with preserved evidence and this new technology, bringing the family closure.

The company that makes the technology says roughly a dozen law enforcement agencies have the instrument in California at this time. Its also in over 20 countries.

The Santa Barbara County Sheriffs Office says they currently have 31 cold cases. The San Luis Obispo County Sheriffs Office says it has 41 cases, mostly dating back to the 1970s and 80s. It adds that its in the process of getting the rapid DNA technology as well.

Continued here:
Detectives turn to rapid DNA technology for clues in 45-year-old cold case - KSBY San Luis Obispo News

New York, April 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Indication, by Workflow, by Application, by End User - United States Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06015233/?utm_source=GNW

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The United States Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from USD 136.80 Million in 2020 to USD 415.57 Million by the end of 2025.2. The United States Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from EUR 119.95 Million in 2020 to EUR 364.38 Million by the end of 2025.3. The United States Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from GBP 106.63 Million in 2020 to GBP 323.93 Million by the end of 2025.4. The United States Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from JPY 14,600.45 Million in 2020 to JPY 44,352.44 Million by the end of 2025.5. The United States Viral Vector & Plasmid DNA Manufacturing Market is expected to grow from AUD 198.65 Million in 2020 to AUD 603.47 Million by the end of 2025.

Market Segmentation & Coverage:This research report categorizes the Viral Vector & Plasmid DNA Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

"The Adeno-Associated Virus is projected to witness the highest growth during the forecast period"

Based on Type, the Viral Vector & Plasmid DNA Manufacturing Market studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA. The Lentivirus commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Adeno-Associated Virus is expected to grow at the fastest CAGR during the forecast period.

"The Infectious Disease is projected to witness the highest growth during the forecast period"

Based on Indication, the Viral Vector & Plasmid DNA Manufacturing Market studied across Cancer, Genetic Disorder, and Infectious Disease. The Cancer commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Infectious Disease is expected to grow at the fastest CAGR during the forecast period.

"The Upstream Processing is projected to witness the highest growth during the forecast period"

Based on Workflow, the Viral Vector & Plasmid DNA Manufacturing Market studied across Downstream Processing and Upstream Processing. The Downstream Processing further studied across Fill-finish and Purification. The Upstream Processing further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting. The Downstream Processing commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Upstream Processing is expected to grow at the fastest CAGR during the forecast period.

"The Vaccinology is projected to witness the highest growth during the forecast period"

Based on Application, the Viral Vector & Plasmid DNA Manufacturing Market studied across Antisense & RNAi, Cell Therapy, Gene Therapy, and Vaccinology. The Gene Therapy commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Vaccinology is expected to grow at the fastest CAGR during the forecast period.

"The Research Institutes is projected to witness the highest growth during the forecast period"

Based on End User, the Viral Vector & Plasmid DNA Manufacturing Market studied across Biotech Companies and Research Institutes. The Biotech Companies commanded the largest size in the Viral Vector & Plasmid DNA Manufacturing Market in 2020. On the other hand, the Research Institutes is expected to grow at the fastest CAGR during the forecast period.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch FPNV Positioning Matrix:The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Viral Vector & Plasmid DNA Manufacturing Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch Competitive Strategic Window:The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the United States Viral Vector & Plasmid DNA Manufacturing Market?2. What are the inhibiting factors and impact of COVID-19 shaping the United States Viral Vector & Plasmid DNA Manufacturing Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Viral Vector & Plasmid DNA Manufacturing Market?4. What is the competitive strategic window for opportunities in the United States Viral Vector & Plasmid DNA Manufacturing Market?5. What are the technology trends and regulatory frameworks in the United States Viral Vector & Plasmid DNA Manufacturing Market?6. What are the modes and strategic moves considered suitable for entering the United States Viral Vector & Plasmid DNA Manufacturing Market?Read the full report: https://www.reportlinker.com/p06015233/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read this article:
Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Indication, by Workflow, by Application, by End User - United States...

LONDON--(BUSINESS WIRE)--The partnership will bring Ecospend's Open Banking innovative payments service to DNA Payments Group portfolio of 30,000 merchants. Sitting alongside their existing suite of products, this latest solution will offer a new alternative way for merchants to accept payments.

Nurlan Zhagiparov, Director of DNA Payments said:

Ecospend's technology gives us the perfect opportunity to deliver the latest payments technology in the market. This latest solution underscores DNA's commitment to innovative thinking and responding to the needs of the market. The partnership with Ecospend will enable our clients to offer an additional cost effective and secure payment solution via Open Banking Payments. After extensively reviewing the market, we found that Ecospend's technology and reach are unrivalled, and we are delighted to announce this partnership.

Metin Erkman, CEO of Ecospend added:

Ecospend has established itself as one of the leading open banking players in the market. We have over 50 UK bank APIs and are developing our European PSD2 model. Soon we will be able to offer all EU users our market-leading bank payment and data-solutions. Having won the HMRC tender and now DNA Payments, we are fast emerging as the key Open Banking platform in Europe. As British industries start to recover from the economic consequences of COVID-19, Open Banking will represent a unique opportunity for businesses to make cost savings while improving security and the quality of the user experience

In the past few months, DNA Payments has launched various new payment methods, including Pay By Bank, Pay By Link, and PayPal. These payment solutions have been rolled out across the DNA Payments Group of companies, including 123Send, Optomany and Active Payments, enabling their customers and merchants to accept payments quicker and easier than ever before.

About DNA Payments

DNA Payments Limited is the largest independent, fully vertically integrated payments company in the UK and EU. The DNA Payments Group consists of the UKs largest independent omnichannel gateway Optomany, which services large corporates and medium size businesses, 123 Send Limited and Active Payments which provide services to SME customers and are two of the largest providers of PaaS and SaaS services to multinational Acquirers and Banks.

DNA Payments is committed to build a transparent business model, so that customers can easily track their money at each stage whilst it is being processed using fast and efficient technology.

DNA Payments Limited is authorised and regulated by the Financial Conduct Authority, under the Payment Services Regulations 2017 for the provision of payment services.

See more here:
DNA Payments Group Announces the Launch of Open Banking Payments - Business Wire

A forensic scientist testified in the trial of Derek Chauvin Wednesday that she found George Floyd's blood and pills with Floyd's DNA in the squad car where Floyd struggled with officers. Chauvin, who was seen in disturbing videos kneeling on Floyd's neck for more than nine minutes, is charged with second-degree murder,third-degree murderand second-degree manslaughter.

McKenzie Anderson, a crime scene team leader with the Minnesota Bureau of Criminal Apprehension, testified that she photographed but didn't collect the pills when she first processed the squad car in May 2020. She also found two pills in the car Floyd was driving when she processed it at the same time. She said she re-processed the squad car at the request of the defense team in January 2021 and collected and tested the pills found in the back seat, confirming they contained Floyd's saliva.

Brehana Giles, a chemist with the Minnesota state Bureau of Criminal Apprehension, then took the stand. She said her testing found that the pills in the squad car contained methamphetamine and potential other substances she could not identify. Prosecutors then called Susan Neith, a forensic chemist based in Pennsylvania who also tested the pills. Neith testified she was able to identify fentanyl as well as methamphetamine in the pills found in the squad car, but she said the methamphetamine level was much lower than typical street meth.

Both chemists found that the pills in the car Floyd was driving contained both methamphetamine and fentanyl, and were marked to look like pharmaceutical drugs. Court recessed for the day following their testimony.

The testimony is significant because the defense has suggested that Floyd, who suffered from heart disease, died of a heart arrhythmia brought on by drugs he ingested and adrenaline. The prosecution argues Floyd died of oxygen deprivation beneath the pressure of Chauvin's knee.

Earlier, LAPD Sergeant Jody Stiger, a prosecution expert in tactics and de-escalation training, testified that Chauvin used deadly force against Floyd. Stiger testified he believed no force was necessary once Floyd was handcuffed, on the ground and no longer resisting.

Stiger testified Tuesday that in his view,officers used excessive forceagainst Floyd during the fatal arrest on May 25, 2020.

"My opinion was the force was excessive," Stiger said.

Stiger told prosecutors he did not believe the crowd of onlookers to pose a threat to officers during the incident, "because they were merely filming, and most of it was their concern for Mr. Floyd." Defense attorney Eric Nelson has attempted to portray the crowd as unruly.

But on cross-examination by Nelson, Stiger acknowledged some of the name-calling and aggressive statements by the crowd could be perceived as a threat.

Chauvin has pleaded not guilty. The other three officers involved are charged with aiding and abetting, and are expected to be tried jointly in August.

Read more here:
Forensic Scientist Found George Floyd's Blood, Pills With His DNA In Squad Car - News On 6

Amanda Garcia was12 years old when she learned her stepfather wasnt her biological dad. Although not knowing has been a source of curiosityand concern over the years, she hasnt decided topursue contact since.

In fact, it wasgeneral healthand ancestryinterests that led the 47-year-old Wilmington woman to take a23andMe DNAtestin October. She was surprised to learn that most of her genetic makeup relates to Europe and the British Isles. And thetest didn't reveal many insights about her health, either.

No, the big shock came with a list of newly discovered family members.

It said I had a cousin, who was actually my half uncle,and he told me I had a half-brother and half-sister,she said.I was stunned, blown away.

More and more people are uncovering such connections through direct-to-consumer genetic testing companies like 23andMe and Ancestry. Test sales started booming around 2017and now millions people have since used such tests.

23andMe said that its tests weren't necessarily designed to confirm parentage and familial relationships, but that an optional DNA Relatives tool is available for test takers. As a result, they are increasingly hearing stories of families discovering and reuniting with newfound relatives.

Garcia had been told some negative things about her father in the past, but she thoughtreaching out throughthese connectionswould be a good way to learn more about a side of her familyshe knew nothing about.

As I was talking to them, all of that fear started to melt away, Garcia said.I learned that I needed to know what happened, and about this whole other side of me.

Soon after, in early January, her half-brother was flying toWilmington fromMinnesota to meet her, and help coordinate a meeting with her father.

The three men were also able to meet Garcias husband, and her four children, aged 3 to 18.Garciaisa homeschoolingmomand admits that shes been a little too busy for the past 18 years to think too much about her past.

As aUNCW alum,she is proud that shewill soon be sending her oldest daughter, a violinist, to the university. Shes also spent a lot of time with her next oldest, a soccer player whoplays travel ball.

Truthfully, I think all of this has happened at the right time, she said. Ive had time to process and am now in a place where I can move forward.

And in recent months, shes been busymaking up for lost time-- bydelivering flowers and Valentines treats to her sister, who lives nearby,andsending herniecea big box of gifts in Minnesota to open via video.

We Facetime, we play games, Garcia said. Its been great.

Garcia is also looking forward to more.

My sister, understandably, has been worried about COVID, Garcia said.I really cant wait to spend more time with her, and for her to meet my family.

The whole process has been such a cathartic experience, that Garcia told23andMe what has happened in her life sinceshe took that test.

I feel like I have closure, she said. I finally can put together those missing pieces.This has given me a lot of peace.

More here:
Wilmington woman will celebrate National Siblings Day with a new half-brother and half-sister - StarNewsOnline.com